\-\ Texto\\:\\ \ \(0\)\
\-\ normal\ \(4026\)\
\-\ right\\ middle\\ and\\ posterior\\ fossa\\ mass\\ involving\\ the\\ cavernous\\ sinus\ \(0\)\
\-\ meningioma\ \(167\)\
\-\ meningioma\ \(167\)\
\-\ schwannoma\ \(67\)\
\-\ granulomatous\\ disease\ \(29\)\
\-\ lymphoma\ \(373\)\
\-\ mets\ \(38\)\
\-\ 45\\ y\\/o\\ with\\ mass\\ seen\\ on\\ ct\ \(0\)\
\-\ meningiomas\\ are\\ the\\ most\\ common\\ extra\\ axial\\ tumors\\.\\ \\ they\\ are\\ derived\\ from\\ meningothelial\\ cells\\ within\\ the\\ arachnoid\\ granulations\\.\\ \\ most\\ meningiomas\\ are\\ sporadic\\ and\\ most\\ commonly\\ occur\\ in\\ middle\\ aged\\ females\\.\\ \\ however\\,\\ multiple\\ meningiomas\\ may\\ be\\ seen\\ in\\ patients\\ with\\ nf2\\,\\ familial\\ or\\ patients\\ status\\-post\\ radiation\\.\\ \\ meningiomas\\ are\\ typically\\ divided\\ into\\ 3\\ categories\\;\\ benign\\,\\ atypical\\ meningioma\\ and\\ anaplastic\\ meningioma\\.\\ \\ most\\ meningiomas\\ are\\ found\\ supartentorial\\ which\\ accounts\\ for\\ approximately\\ 90\\ percent\\.\\ \\ the\\ cerebellopontine\\ angle\\ location\\ makes\\ up\\ less\\ than\\ 5\\ percent\\ of\\ all\\ meningiomas\\.\\ \\ imaging\\ characteristics\\ of\\ meningiomas\\ under\\ ct\\ are\\ hyper\\ to\\ isodense\\ and\\ demonstrate\\ strong\\ enhancement\\.\\ \\ many\\ will\\ show\\ calcification\\ or\\ cystic\\ areas\\ and\\ up\\ to\\ 20\\ percent\\ may\\ show\\ a\\ bony\\ change\\ such\\ as\\ hyperostosis\\.\\ \\ imaging\\ characterics\\ under\\ mr\\ are\\ isointense\\ on\\ t1\\,\\ hyperintense\\ on\\ t2\\ and\\ will\\ show\\ strong\\ enhancement\\ with\\ the\\ possibility\\ of\\ a\\ dural\\ tail\\.\\ \\ angiography\\ may\\ demonstrate\\ a\\ spoke\\ wheel\\ appearance\\ with\\ a\\ persistant\\ blush\\,\\ strong\\ early\\ uptake\\ of\\ contrast\\ and\\ will\\ persist\\ through\\ the\\ venous\\ phase\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ meningiomas\\:\\ 0\\.5703124282553376\ \(0\)\
\-\ strong\\:\\ 0\\.21750097093356482\ \(0\)\
\-\ meningioma\\:\\ 0\\.2085271449891941\ \(0\)\
\-\ percent\\:\\ 0\\.20640774443240137\ \(0\)\
\-\ are\\:\\ 0\\.18479580212279373\ \(0\)\
\-\ most\\:\\ 0\\.14482944959765895\ \(0\)\
\-\ will\\:\\ 0\\.13433515285460204\ \(0\)\
\-\ show\\:\\ 0\\.1324976713643072\ \(0\)\
\-\ under\\:\\ 0\\.11517956169050321\ \(0\)\
\-\ supartentorial\\:\\ 0\\.11126073348922225\ \(0\)\
\-\ characterics\\:\\ 0\\.11126073348922225\ \(0\)\
\-\ meningothelial\\:\\ 0\\.10631557062951145\ \(0\)\
\-\ granulations\\:\\ 0\\.10631557062951145\ \(0\)\
\-\ spoke\\:\\ 0\\.10631557062951145\ \(0\)\
\-\ may\\:\\ 0\\.10503243433045707\ \(0\)\
\-\ and\\:\\ 0\\.10063337770954195\ \(0\)\
\-\ middle\\:\\ 0\\.09949949504951415\ \(0\)\
\-\ nf2\\:\\ 0\\.09435310999672733\ \(0\)\
\-\ persistant\\:\\ 0\\.09163159048672148\ \(0\)\
\-\ blush\\:\\ 0\\.08668642762701068\ \(0\)\
\-\ derived\\:\\ 0\\.08515990385575757\ \(0\)\
\-\ wheel\\:\\ 0\\.08515990385575757\ \(0\)\
\-\ the\\:\\ 0\\.08329277928145996\ \(0\)\
\-\ categories\\:\\ 0\\.08258272061353525\ \(0\)\
\-\ enhancement\\:\\ 0\\.08008883512893981\ \(0\)\
\-\ hyperostosis\\:\\ 0\\.07997791273372044\ \(0\)\
\-\ sporadic\\:\\ 0\\.07907407172699858\ \(0\)\
\-\ persist\\:\\ 0\\.07907407172699858\ \(0\)\
\-\ patients\\:\\ 0\\.07827608137318325\ \(0\)\
\-\ cerebellopontine\\:\\ 0\\.07783270227350532\ \(0\)\
\-\ isodense\\:\\ 0\\.07783270227350532\ \(0\)\
\-\ divided\\:\\ 0\\.0774454865042324\ \(0\)\
\-\ accounts\\:\\ 0\\.0774454865042324\ \(0\)\
\-\ anaplastic\\:\\ 0\\.07635255221699273\ \(0\)\
\-\ aged\\:\\ 0\\.07600897253105827\ \(0\)\
\-\ familial\\:\\ 0\\.07567480718158733\ \(0\)\
\-\ hyper\\:\\ 0\\.07534955397886509\ \(0\)\
\-\ imaging\\:\\ 0\\.07312485441439656\ \(0\)\
\-\ demonstrate\\:\\ 0\\.07233708268160748\ \(0\)\
\-\ mets\\:\\ 0\\.07152410098747297\ \(0\)\
\-\ females\\:\\ 0\\.06998378832579359\ \(0\)\
\-\ makes\\:\\ 0\\.06977880413451575\ \(0\)\
\-\ up\\:\\ 0\\.06882926868230868\ \(0\)\
\-\ tail\\:\\ 0\\.06861637523028813\ \(0\)\
\-\ seen\\:\\ 0\\.06550784480387072\ \(0\)\
\-\ possibility\\:\\ 0\\.0646988744639917\ \(0\)\
\-\ angiography\\:\\ 0\\.06430328500933463\ \(0\)\
\-\ characteristics\\:\\ 0\\.06379503345726985\ \(0\)\
\-\ arachnoid\\:\\ 0\\.06354863573797323\ \(0\)\
\-\ on\\:\\ 0\\.06303579167550605\ \(0\)\
\-\ isointense\\:\\ 0\\.06295357761103447\ \(0\)\
\-\ granulomatous\\:\\ 0\\.06184406103397602\ \(0\)\
\-\ dural\\:\\ 0\\.06173846494331838\ \(0\)\
\-\ angle\\:\\ 0\\.06102383456173946\ \(0\)\
\-\ cavernous\\:\\ 0\\.06034876973121967\ \(0\)\
\-\ schwannoma\\:\\ 0\\.059620417684271065\ \(0\)\
\-\ phase\\:\\ 0\\.059532357574036215\ \(0\)\
\-\ extra\\:\\ 0\\.05844193048637016\ \(0\)\
\-\ atypical\\:\\ 0\\.057076949107009334\ \(0\)\
\-\ 45\\:\\ 0\\.05578477140161873\ \(0\)\
\-\ 90\\:\\ 0\\.05559270015202667\ \(0\)\
\-\ hyperintense\\:\\ 0\\.05534122171102238\ \(0\)\
\-\ many\\:\\ 0\\.05485330575730438\ \(0\)\
\-\ fossa\\:\\ 0\\.05461647749497805\ \(0\)\
\-\ with\\:\\ 0\\.0544922497377038\ \(0\)\
\-\ of\\:\\ 0\\.05445971007391167\ \(0\)\
\-\ cells\\:\\ 0\\.05360422446524691\ \(0\)\
\-\ bony\\:\\ 0\\.05360422446524691\ \(0\)\
\-\ uptake\\:\\ 0\\.05349676762665937\ \(0\)\
\-\ mass\\:\\ 0\\.05314927423007565\ \(0\)\
\-\ ct\\:\\ 0\\.052973407970308785\ \(0\)\
\-\ change\\:\\ 0\\.05271967220567841\ \(0\)\
\-\ commonly\\:\\ 0\\.05147992190549423\ \(0\)\
\-\ tumors\\:\\ 0\\.0511666059380236\ \(0\)\
\-\ occur\\:\\ 0\\.0511666059380236\ \(0\)\
\-\ sinus\\:\\ 0\\.05027223776461906\ \(0\)\
\-\ early\\:\\ 0\\.05014966113201497\ \(0\)\
\-\ they\\:\\ 0\\.04971046803095699\ \(0\)\
\-\ calcification\\:\\ 0\\.04967131463526726\ \(0\)\
\-\ venous\\:\\ 0\\.04967131463526726\ \(0\)\
\-\ typically\\:\\ 0\\.0488402874106873\ \(0\)\
\-\ involving\\:\\ 0\\.04873122910771691\ \(0\)\
\-\ location\\:\\ 0\\.04844508642801775\ \(0\)\
\-\ or\\:\\ 0\\.048405702381295844\ \(0\)\
\-\ benign\\:\\ 0\\.04779125097149677\ \(0\)\
\-\ less\\:\\ 0\\.04733095965537126\ \(0\)\
\-\ areas\\:\\ 0\\.04723454593365715\ \(0\)\
\-\ radiation\\:\\ 0\\.04610417032588924\ \(0\)\
\-\ found\\:\\ 0\\.04501623895344574\ \(0\)\
\-\ mr\\:\\ 0\\.04501623895344574\ \(0\)\
\-\ 20\\:\\ 0\\.04488352521431193\ \(0\)\
\-\ such\\:\\ 0\\.044752240068461784\ \(0\)\
\-\ approximately\\:\\ 0\\.04439198642608551\ \(0\)\
\-\ t1\\:\\ 0\\.043347687756250405\ \(0\)\
\-\ appearance\\:\\ 0\\.04194224710506412\ \(0\)\
\-\ cystic\\:\\ 0\\.04190083357704535\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04143441886564477\ \(0\)\
\-\ all\\:\\ 0\\.04141453903682122\ \(0\)\
\-\ through\\:\\ 0\\.04141453903682122\ \(0\)\
\-\ however\\:\\ 0\\.04117847478441044\ \(0\)\
\-\ axial\\:\\ 0\\.0401872745100025\ \(0\)\
\-\ t2\\:\\ 0\\.04002667752893066\ \(0\)\
\-\ common\\:\\ 0\\.03945527852150217\ \(0\)\
\-\ than\\:\\ 0\\.03943837446850794\ \(0\)\
\-\ into\\:\\ 0\\.03698326410531033\ \(0\)\
\-\ posterior\\:\\ 0\\.03597626822132047\ \(0\)\
\-\ to\\:\\ 0\\.03478571405475362\ \(0\)\
\-\ in\\:\\ 0\\.03461449884221981\ \(0\)\
\-\ multiple\\:\\ 0\\.03402916701605086\ \(0\)\
\-\ contrast\\:\\ 0\\.033803602050461234\ \(0\)\
\-\ within\\:\\ 0\\.03204270621914222\ \(0\)\
\-\ which\\:\\ 0\\.031635069127704925\ \(0\)\
\-\ disease\\:\\ 0\\.029203843436832355\ \(0\)\
\-\ normal\\:\\ 0\\.0284057707914804\ \(0\)\
\-\ be\\:\\ 0\\.028222568820188018\ \(0\)\
\-\ as\\:\\ 0\\.027949531393094126\ \(0\)\
\-\ from\\:\\ 0\\.027631038825582762\ \(0\)\
\-\ right\\:\\ 0\\.023065988228501165\ \(0\)\
\-\ for\\:\\ 0\\.021086731604274062\ \(0\)\
